The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy
Open accessAbstract
OBJECTIVE: Diabetic nephropathy is one of the most common causes of end-stage renal failure. Inhibition of ACE2 function accelerates diabetic kidney injury, whereas renal ACE2 is downregulated in diabetic nephropathy. We examined the ability of human recombinant ACE2 (hrACE2) to slow the progression of diabetic kidney injury. RESEARCH DESIGN AND METHODS: Male 12-week-old diabetic Akita mice (Ins2WT/C96Y) and control C57BL/6J mice (Ins2WT/WT) were injected daily with placebo or with rhACE2 (2 mg/kg, i.p.) for 4 weeks. Albumin excretion, gene expression, histomorphometry, NADPH oxidase activity, and peptide levels were examined. The effect of hrACE2 on high glucose and angiotensin II (ANG II)–induced changes was also examined in cultured mesangial cells. RESULTS: Treatment with hrACE2 increased plasma ACE2 activity, normalized blood pressure, and reduced the urinary albumin excretion in Akita Ins2WT/C96Y mice in association with a decreased glomerular mesangial matrix expansion and normalization of increased α-smooth muscle actin and collagen III expression. Human recombinant ACE2 increased ANG 1–7 levels, lowered ANG II levels, and reduced NADPH oxidase activity. mRNA levels for p47phox and NOX2 and protein levels for protein kinase Cα (PKCα) and PKCβ1 were also normalized by treatment with hrACE2. In vitro, hrACE2 attenuated both high glucose and ANG II–induced oxidative stress and NADPH oxidase activity. CONCLUSIONS: Treatment with hrACE2 attenuates diabetic kidney injury in the Akita mouse in association with a reduction in blood pressure and a decrease in NADPH oxidase activity. In vitro studies show that the protective effect of hrACE2 is due to reduction in ANG II and an increase in ANG 1–7 signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
A Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,009
Levey, A. S., Atkins, R., Coresh, J., Cohen, E. P., Collins, A. J., Eckardt, K.-U., Nahas, M. E., Jaber, B. L., Jadoul, M., Levin, A., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002343 · Cited by 1,516
Regression of Microalbuminuria in Type 1 Diabetes
Perkins, B. A., Ficociello, L. H., Silva, K. H., Finkelstein, D. M., Warram, J. H., & Krolewski, A. S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021835 · Cited by 801
Pathogenesis, prevention, and treatment of diabetic nephropathy
Cooper, M. E. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01346-4 · Cited by 560
ACE2: from vasopeptidase to SARS virus receptor
Turner, A. J., Hiscox, J. A., & Hooper, N. M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.001 · Cited by 517
The emerging role of ACE2 in physiology and disease
Hamming, I., Cooper, M., Haagmans, B., Hooper, N., Korstanje, R., Osterhaus, A., Timens, W., Turner, A., Navis, G., & van Goor, H. (2007) · The Journal of Pathology · doi:10.1002/path.2162 · Cited by 434
Tesch, G. H. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00016.2008 · Cited by 417
Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy
Tikellis, C., Johnston, C. I., Forbes, J. M., Burns, W. C., Burrell, L. M., Risvanis, J., & Cooper, M. E. (2003) · Hypertension · doi:10.1161/01.hyp.0000060689.38912.cb · Cited by 350
Thallas-Bonke, V., Thorpe, S. R., Coughlan, M. T., Fukami, K., Yap, F. Y. T., Sourris, K. C., Penfold, S. A., Bach, L. A., Cooper, M. E., & Forbes, J. M. (2008) · Diabetes · doi:10.2337/db07-1119 · Cited by 345
ACE and ACE2 Activity in Diabetic Mice
Wysocki, J., Ye, M., Soler, M. J., Gurley, S. B., Xiao, H. D., Bernstein, K. E., Coffman, T. M., Chen, S., & Batlle, D. (2006) · Diabetes · doi:10.2337/db06-0033 · Cited by 339
Impact of genetic background on nephropathy in diabetic mice
Gurley, S. B., Clare, S. E., Snow, K. P., Hu, A., Meyer, T. W., & Coffman, T. M. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00204.2005 · Cited by 286
Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury
Wong, D. W., Oudit, G. Y., Reich, H., Kassiri, Z., Zhou, J., Liu, Q. C., Backx, P. H., Penninger, J. M., Herzenberg, A. M., & Scholey, J. W. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060977 · Cited by 273
Self-citationThe Role of ACE2 in Cardiovascular Physiology
Oudit, G. Y., Crackower, M. A., Backx, P. H., & Penninger, J. M. (2003) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(02)00233-5 · Cited by 254
Self-citationReich, H. N., Oudit, G. Y., Penninger, J. M., Scholey, J. W., & Herzenberg, A. M. (2008) · Kidney International · doi:10.1038/ki.2008.497 · Cited by 252
Self-citationOudit, G. Y., Herzenberg, A. M., Kassiri, Z., Wong, D., Reich, H., Khokha, R., Crackower, M. A., Backx, P. H., Penninger, J. M., & Scholey, J. W. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.051091 · Cited by 232
Self-citationThe intrarenal renin–angiotensin system and diabetic nephropathy
Carey, R. M., & Siragy, H. M. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(03)00111-5 · Cited by 230
Vidotti, D. B., Casarini, D. E., Cristovam, P. C., Leite, C. A., Schor, N., & Boim, M. A. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00371.2003 · Cited by 224
Ye, M., Wysocki, J., Naaz, P., Salabat, M. R., LaPointe, M. S., & Batlle, D. (2004) · Hypertension · doi:10.1161/01.hyp.0000126192.27644.76 · Cited by 221
Expression of ACE and ACE2 in Individuals With Diabetic Kidney Disease and Healthy Controls
Mizuiri, S., Hemmi, H., Arita, M., Ohashi, Y., Tanaka, Y., Miyagi, M., Sakai, K., Ishikawa, Y., Shibuya, K., Hase, H., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.11.022 · Cited by 218
Soler, M. J., Wysocki, J., Ye, M., Lloveras, J., Kanwar, Y., & Batlle, D. (2007) · Kidney International · doi:10.1038/sj.ki.5002373 · Cited by 217
Novel Peptide Inhibitors of Angiotensin-converting Enzyme 2
Huang, L., Sexton, D. J., Skogerson, K., Devlin, M., Smith, R., Sanyal, I., Parry, T., Kent, R., Enright, J., Wu, Q.-L., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212934200 · Cited by 215
Benter, I. F., Yousif, M. H. M., Dhaunsi, G. S., Kaur, J., Chappell, M. C., & Diz, D. I. (2008) · American Journal of Nephrology · doi:10.1159/000108758 · Cited by 204
Su, Z., Zimpelmann, J., & Burns, K. D. (2006) · Kidney International · doi:10.1038/sj.ki.5001509 · Cited by 196
Ohshiro, Y., Ma, R. C., Yasuda, Y., Hiraoka-Yamamoto, J., Clermont, A. C., Isshiki, K., Yagi, K., Arikawa, E., Kern, T. S., & King, G. L. (2006) · Diabetes · doi:10.2337/db06-0895 · Cited by 188
ACE2 Deficiency Modifies Renoprotection Afforded by ACE Inhibition in Experimental Diabetes
Tikellis, C., Bialkowski, K., Pete, J., Sheehy, K., Su, Q., Johnston, C., Cooper, M. E., & Thomas, M. C. (2008) · Diabetes · doi:10.2337/db07-1212 · Cited by 182
Kelly, D. J., Zhang, Y., Hepper, C., Gow, R. M., Jaworski, K., Kemp, B. E., Wilkinson-Berka, J. L., & Gilbert, R. E. (2003) · Diabetes · doi:10.2337/diabetes.52.2.512 · Cited by 166
Pinheiro, S. V. B., Ferreira, A. J., Kitten, G. T., da Silveira, K. D., da Silva, D. A., Santos, S. H. S., Gava, E., Castro, C. H., Magalhães, J. A., da Mota, R. K., et al. (2009) · Kidney International · doi:10.1038/ki.2009.61 · Cited by 157
Huang, W., Gallois, Y., Bouby, N., Bruneval, P., Heudes, D., Belair, M., Krege, J. H., Meneton, P., Marre, M., Smithies, O., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231476798 · Cited by 151
Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor
Kakoki, M., Takahashi, N., Jennette, J. C., & Smithies, O. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405449101 · Cited by 142
Loss of TIMP3 Enhances Interstitial Nephritis and Fibrosis
Kassiri, Z., Oudit, G. Y., Kandalam, V., Awad, A., Wang, X., Ziou, X., Maeda, N., Herzenberg, A. M., & Scholey, J. W. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008050492 · Cited by 139
Self-citationACE-inhibitor use and the long-term risk of renal failure in diabetes
Suissa, S., Hutchinson, T., Brophy, J. M., & Kezouh, A. (2006) · Kidney International · doi:10.1038/sj.ki.5000159 · Cited by 128
Prevention and treatment of diabetic nephropathy
Wittmann, I., Molnár, G. A., Degrell, P., Wagner, Z., Tamaskó, M., Laczy, B., Brasnyó, P., Wagner, L. J., & Nagy, J. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.011 · Cited by 116
Chappell, M. C., Modrall, J. G., Diz, D. I., & Ferrario, C. M. (2004) · KARGER eBooks · doi:10.1159/000078713 · Cited by 105
Pharmacologic modulation of ACE2 expression
Soler, M. J., Barrios, C., Oliva, R., & BATLLE, D. C. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0076-0 · Cited by 88
Levey, A. S., Andreoli, S. P., DuBose, T. D., Provenzano, R., & Collins, A. J. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121305 · Cited by 56
Cristovam, P. C., Arnoni, C. P., de Andrade, M. C. C., Casarini, D. E., Pereira, L. G., Schor, N., & Boim, M. A. (2008) · Experimental Biology and Medicine · doi:10.3181/0708-rm-229 · Cited by 52
The role of ACE2 in pulmonary diseases--relevance for the nephrologist
Oudit, G. Y., Imai, Y., Kuba, K., Scholey, J. W., & Penninger, J. M. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp065 · Cited by 28
Self-citation
Cited by
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317015 · Cited by 1,882
Self-citationRole of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure
Patel, V. B., Zhong, J.-C., Grant, M. B., & Oudit, G. Y. (2016) · Circulation Research · doi:10.1161/circresaha.116.307708 · Cited by 833
Self-citationTikellis, C., & Thomas, M. C. (2012) · International Journal of Peptides · doi:10.1155/2012/256294 · Cited by 624
Cheng, H., Wang, Y., & Wang, G. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25785 · Cited by 548
ACE2, angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosis
Simões e Silva, A., Silveira, K., Ferreira, A., & Teixeira, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12159 · Cited by 542
Metadata
- Authors
- Oudit, G. Y., Liu, G. C., Zhong, J., Basu, R., Chow, F. L., Zhou, J., Loibner, H., Janzek, E., Schuster, M., Penninger, J. M., Herzenberg, A. M., Kassiri, Z., & Scholey, J. W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-11-23
- Volume
- 59
- Issue
- 2
- Pages
- 529-538
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2053710318
- Cited by
- 300
- References
- 44
- FWCI
- 14.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.